LEXX (Lexaria Bioscience) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


LEXX Lexaria Bioscience Corp LEXX
28 GF Score
Price $0.54
GF Value $0.75
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lexaria Bioscience Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Lexaria Bioscience's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LEXX vs MBRX, ICU, INTI: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Lexaria Bioscience's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexaria Bioscience Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Margin of Safety % (DCF Earnings Based) falls into.


LEXX
28GF Score
Lexaria Bioscience Corp LEXX
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be undervalued. The current stock price of $0.54 is trading 27.7% below its estimated GF Value™ of $0.75. GuruFocus considers Lexaria Bioscience to be Modestly Undervalued.

Key valuation signals for LEXX:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $0.75 vs. price of $0.54 (27.7% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
28GF Score

Get the complete analysis for LEXX

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price
$0.75
GF Value